Melissa Santibañez

Melissa Santibañez

Auto-generated profile, based on publicly available information

Melissa Santibañez

Nova Southeastern University Barry and Judy Silverman College of Pharmacy Fort Lauderdale Florida USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

14 April 2019 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
KBKaren Berger
Karen Berger
MSMelissa Santibañez
Melissa Santibañez
LLLina Lin
Lina Lin
CLChristine A. Lesch
Christine A. Lesch
Purpose: Current guidelines favor 4F-PCC over plasma for reversal of warfarin. Uncertainty remains on the hemostatic effectiveness and thrombotic risk of 4F-PCC for direct-acting oral anticoagulants (DOACs), particularly in patients with intracranial hemorrhage (ICH). This study sought to evaluate the effectiveness and safety of a lower dose protocol of 25 units/kg 4F-PCC for the management of DOAC-associated ICH in a real-world setting. Materials and Methods: This was a retrospective study of adult patients who received at least one dose of 4F-PCC from March 2014 to December 2015 for DOAC-associated ICH. The primary outcome was hemostatic effectiveness within 24 hours. The secondary outcome was thromboembolic events within 14 days. Results: Twenty-two patients received 4F-PCC for DOAC-associated ICH and were included in the analysis. Hemostasis was evaluable in 19 patients with post-4F-PCC imaging available and occurred in 18/19 (94.7%) patients. Thromboembolism occurred in 2 out of 22 patients (9.1%). Conclusions: The use of a lower dose protocol of 25 units/kg of 4F-PCC resulted in high rates of hemostasis in patients with DOAC-associated ICH. Two patients developed thrombotic events within 14 days of 4F-PCC administration.

19 July 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PBPaul Boylan
Paul Boylan
MAMaha Abdalla
Maha Abdalla
BBBrittany Bissell
Brittany Bissell
MMMark A. Malesker
Mark A. Malesker
MSMelissa Santibañez
Melissa Santibañez
ZSZachary Smith
Zachary Smith

22 July 2023 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
UAUzair S. Ali
Uzair S. Ali
GHGenevieve Marie Hale
Genevieve Marie Hale
MSMelissa Santibañez
Melissa Santibañez
KBKaren Berger
Karen Berger
KBKathleen Baldwin
Kathleen Baldwin

1 April 2021 in Journal of Critical Care
Verified
Journal Article
Closed access
MCMelanie Smith Condeni
Melanie Smith Condeni
ABAlyson T. Basting
Alyson T. Basting
PCPatrick G. Costello
Patrick G. Costello
ADAshley DePriest
Ashley DePriest
EEEvert A. Eriksson
Evert A. Eriksson
ANAndrea Newsome
Andrea Newsome

19 September 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMelissa Santibañez
Melissa Santibañez
KBKristen Bunnell
Kristen Bunnell
AHAmanda Harrington
Amanda Harrington
SBSusan Bleasdale
Susan Bleasdale
EWEric Wenzler
Eric Wenzler
Evidence on pharmacokinetic/pharmacodynamic (PK/PD) alterations and clinical outcomes in obese patients with serious infections remains limited. This study aimed to evaluate predicted PK/PD indices of efficacy and observed clinical outcomes between obese and nonobese patients receiving cefepime or piperacillin-tazobactam for Enterobacteriaceae bacteremia. This was a retrospective study of adult inpatients from 1/2012 to 9/2015 with Enterobacteriaceae bacteremia who received empiric cefepime or piperacillin-tazobactam. The primary outcome was clinical cure. First-dose free-drug exposure was estimated via predicted concentrations generated from population PK analyses and used to assess PD target attainment (>50% fT > minimum inhibitory concentration [MIC]) for the specific Enterobacteriaceae isolate. Multivariable logistic regression was utilized to identify independent predictors of clinical cure. One hundred forty-two patients were included, 57 obese and 85 nonobese. Clinical cure was achieved in 68.4% of obese and 62.4% of nonobese patients (P = .458). No significant difference in outcomes was observed when evaluated by World Health Organization (WHO) obesity classes. The PK/PD target was achieved in 98.2% of obese and 91.8% of nonobese patients (P = .144). Independent predictors of clinical cure were immunosuppression and a shorter duration of bacteremia. Obesity was not identified as a significant predictor of clinical outcomes. Neither predicted PK/PD parameters nor clinical outcomes differed significantly between obese and nonobese patients treated with piperacillin-tazobactam or cefepime. As the majority of patients received extended-infusion piperacillin-tazobactam for bacteremia due to pathogens with low MICs, the potentially detrimental pathophysiologic derangements caused by obesity may not have been realized. Further studies are warranted to establish the optimal treatment of serious infections in obese patients.